The feasibility and influencing factor of endoscopic ultrasound-guided tissue acquisition for next-generation sequencing in pancreatic ductal adenocarcinoma patients.

Authors

Meng-Meng Zhang, Wen Shi, Huan-Wen Wu, Jun-Liang Lu, Jie Gao, Xi Wu, Dong-Sheng Wu, Tao Guo, Qing-Wei Jiang, Qiang Wang, Sheng-Yu Zhang, Yun-Lu Feng, Ai-Ming Yang

Published in

Hepatobiliary & pancreatic diseases international : HBPD INT. Sep 17, 2026. Epub Sep 17, 2026.

Abstract

Next-generation sequencing (NGS) is increasingly used in patients with pancreatic ductal adenocarcinoma (PDAC) to identify potential therapeutic targets. Endoscopic ultrasound-guided tissue acquisition (EUS-TA) plays a crucial role in PDAC diagnosis. However, the adequacy of EUS-TA samples for NGS testing is still controversial, and the effect of tumor and procedural factors on the success rate of NGS is not clear. Herein, we aimed to evaluate the adequacy of EUS-TA samples for NGS analysis and identify potential influencing factors.
This study included patients diagnosed with PDAC, who received NGS testing using EUS-TA specimens at Peking Union Medical College Hospital from January 2018 to August 2024. Tumor, procedural, sample quality control of NGS and genetic alteration data were recorded and analyzed.
Among the 125 specimens undergoing NGS testing obtained from EUS-TA, 112 (89.6%) were qualified for NGS. There were no significant differences in tumor location, size, number of passes, and storage time of formalin-fixed paraffin-embedded (FFPE) samples between the qualified and unqualified groups. EUS-TA samples had lower DNA yield but higher DNA quality than that in surgical specimens. The DNA amounts and quality grades in agarose gel electrophoresis were similar in the samples acquired from endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and endoscopic ultrasound guided fine needle biopsy (EUS-FNB) (P > 0.05). Different sizes of needles did not significantly influence DNA yield and quality as well. In total, the most common gene mutations identified in EUS-TA samples were KRAS (82.9%), TP53 (69.1%), CDKN2A (30.1%) and SMAD4 (18.7%).
EUS-TA samples are adequate for subsequent NGS testing. Tumor characteristics, procedural factors, and the types or sizes of needles do not significantly affect the success rate of NGS, suggesting EUS-FNA/FNB as a reliable and stable method for NGS testing in PDAC patients.

PMID:
42844143
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.